Literature DB >> 33936982

Role of 18F-FDG PET/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors.

Guangyu Ma1, Xiaojun Zhang1, Minshu Wang1, Xiaodan Xu1, Baixuan Xu1, Zhiwei Guan1.   

Abstract

BACKGROUND: This retrospective study was performed to estimate the clinical role of whole-body positron emission tomography/computed tomography (PET/CT) using 2-[18F] fluoro-2-deoxy-D-glucose (FDG) in the differential diagnosis of primary benign and malignant unilateral adrenal tumors.
METHODS: A total of 64 patients (31 male, 33 female; age range: 3-76 years, mean: 48.5) with a confirmed unilateral adrenal tumor underwent 18F-FDG PET/CT examination for diagnosis and staging. The whole-body 18F-FDG PET/CT examination excluded metastasis, and all patients were confirmed by operation and biopsy pathology. Their clinical data and pathological results were collected. On visual analysis of PET/CT imaging, adrenal uptake was based on a three-scale grading system. The region of interest (ROI) was delineated in the liver and the renal lesion site. Standardized uptake value (SUV) measurements were determined on a standardized reconstruction, and the maximum values (SUVmax) of the lesion and liver were measured. The ratio of tumor to the liver was defined as T/L. Visual interpretation, SUVmax-receiver operating characteristics (ROC) method, and T/L-ROC method were used to analyze the diagnostic accuracy.
RESULTS: A total of 64 lesions (48 benign, 16 malignant lesions) were detected. The visual analysis found that 100% of Grade I cases were benign, 90.9% of Grade II cases were benign, and 65.1% of Grade III cases were benign. The SUVmax of malignant lesions (10.0±5.8) was higher than that of benign lesions (5.4±5.3, P<0.05). The T/L was 3.39±1.79 for malignant lesions and 1.99±2.09 for benign lesions (P<0.05). In the differentiation of primary benign and malignant unilateral adrenal tumors, the sensitivity, specificity, and accuracy of the SUVmax-ROC method (cut-off value =5.65) were 81.25%, 72.91%, 75.00%, and the positive and negative predictive values were 50.00% and 92.11%, respectively. The sensitivity, specificity, and accuracy of the T/L-ROC method (cut-off value =1.52) were 93.73%, 62.50%, 70.31%, and the positive and negative predictive values were 46.88% and 96.77%, respectively.
CONCLUSIONS: 18F-FDG PET/CT improved diagnostic accuracy in differentiating primary benign and malignant unilateral adrenal tumors. There was a high negative predictive value, and for positive prediction, other tracer imaging is needed for differential diagnosis. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  18F-FDG; differential diagnosis; positron emission tomography/computed tomography (PET/CT); primary adrenal tumor

Year:  2021        PMID: 33936982      PMCID: PMC8047365          DOI: 10.21037/qims-20-875

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  12 in total

Review 1.  Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization.

Authors:  Giles W L Boland; Michael A Blake; Peter F Hahn; William W Mayo-Smith
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

Review 2.  Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.

Authors:  Asha Kandathil; Ka Kit Wong; Daniel J Wale; Maria Chiara Zatelli; Anna Margherita Maffione; Milton D Gross; Domenico Rubello
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

3.  The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.

Authors:  Pelin Ozcan Kara; Taylan Kara; Gonca Kara Gedik; Fatih Kara; Ozlem Sahin; Emel Ceylan Gunay; Oktay Sari
Journal:  Nucl Med Commun       Date:  2011-02       Impact factor: 1.690

4.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Authors:  Murat Fani Bozkurt; Irene Virgolini; Sona Balogova; Mohsen Beheshti; Domenico Rubello; Clemens Decristoforo; Valentina Ambrosini; Andreas Kjaer; Roberto Delgado-Bolton; Jolanta Kunikowska; Wim J G Oyen; Arturo Chiti; Francesco Giammarile; Anders Sundin; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

Review 5.  Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance.

Authors:  Giles W L Boland; Ben A Dwamena; Minal Jagtiani Sangwaiya; Alexander G Goehler; Michael A Blake; Peter F Hahn; James A Scott; Mannudeep K Kalra
Journal:  Radiology       Date:  2011-02-17       Impact factor: 11.105

6.  Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer.

Authors:  N C Gupta; G M Graeber; W J Tamim; J S Rogers; L Irisari; H A Bishop
Journal:  Clin Lung Cancer       Date:  2001-08       Impact factor: 4.785

7.  Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer.

Authors:  Raghunandan Vikram; Henry D W Yeung; Homer A Macapinlac; Revathy B Iyer
Journal:  AJR Am J Roentgenol       Date:  2008-11       Impact factor: 3.959

Review 8.  Molecular imaging of adrenal neoplasms.

Authors:  Clara C Chen; Jorge A Carrasquillo
Journal:  J Surg Oncol       Date:  2012-05-24       Impact factor: 2.885

9.  Imaging of adrenal masses with emphasis on adrenocortical tumors.

Authors:  Anders Sundin
Journal:  Theranostics       Date:  2012-05-17       Impact factor: 11.556

10.  (18)F-FDG PET versus (18)F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients.

Authors:  Yon Mi Sung; Kyung Soo Lee; Byung Tae Kim; Joon Young Choi; Myung Jin Chung; Young Mog Shim; Chin A Yi; Tae Sung Kim
Journal:  Korean J Radiol       Date:  2008 Jan-Feb       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.